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Abstract: Because breast cancer is complicated at the pathological, histological, clinical, and molecular levels, identification of new
genetic targets against carcinogenic pathways is required to generate clinically relevant treatment options. In the current study, ubiquitinspecific protease 7 (USP7), which regulates various cellular pathways including Mdm2, p53, and NF–κB, was selected as a potential gene
editing strategy for breast cancer in vitro. Anticancer activity of USP7 gene suppression has been evaluated through cell proliferation,
gene expression, cell cycle, sphere dissemination, and cell migration analysis. Here, siRNA and shRNA strategies and an allosteric
small-molecule inhibitor of USP7 were used to define potential anticancer activity against MCF7 and T47D human breast cancer cell
lines. Both blockage of deubiquitination by p5091 and knockdown of USP7 reduced cell proliferation, cell migration, colony formation,
and sphere dissemination for both MCF7 and T47D breast cancer cell lines. Restriction of USP7 activity strongly enhanced apoptotic
gene expression and reduced metastatic ability of breast cancer cell lines. This study describes one potential molecular target for the
suppression of breast cancer proliferation and metastasis. Identification of USP7 as a promising gene editing candidate might open up
the possibility of new molecular drug research in targeting the ubiquitination pathway in cancer.
Key words: Ubiquitination, breast cancer, USP7, p5091, gene editing

1. Introduction
Breast cancer is abnormal cell proliferation in the ductal
and gland regions of the breast tissue. Breast cancer is
the most common cancer among women and accounts
for 30% of all newly diagnosed cases of cancer in the
female population. The estimated number of breast cancer
patients and deaths by the end of 2020 in the United States
will be approximately 279,100 and 42,690 respectively
(Siegel et al., 2020). Treatment options for breast cancer
are various and challenging due to the complex nature
of the disease and the different subtypes with diverse
biological properties and metastatic ability (Lyden et al.,
2011). Treatment strategy is based on the cancer stage,
aggressiveness, cell surface (HER2), and steroid hormone
receptors expression (PR and ER) profile, which affect
mortality (Al-Mahmood et al., 2018). Breast cancer
is a multistep process regulated by the activation and
suppression of several molecular pathways which control
the cellular behavior and carcinogenesis process at the
molecular level. Identification of molecular mechanisms
that are responsible for breast cancer development is
important in order to generate more specific treatments.
Breast cancer cell lines MCF7 and T47D, which are both
classified as Luminal A (ERα+, PR+/–, and HER2–) (Yu

et al., 2017), differ in p53 mutation status. The MCF7 cell
line has a wild-type p53 protein (Lim et al., 2009), while
T47D has a L194F mutation in its p53 protein (Parrales
and Iwakuma, 2015). MCF7 and T47D cell lines were
used to compare the effect of USP7 with the p53 protein
pathway as approximately half of cancer patients carry the
mutant p53 protein (Gasco et al., 2002), which has been
correlated with poor prognosis in breast cancer patients
(Lai et al., 2004).
Ubiquitination is one of the main mediators of
posttranslational protein modifications that control major
breast cancer pathways (Ohta and Fukuda, 2004). Although
previous studies have mainly focused on phosphorylation
as a posttranslational modification, recent studies have
proved that ubiquitination has a crucial role in various
signaling and cell regulatory pathways in breast cancer (Pal
and Donato, 2014). Ubiquitination and deubiquitination
of proteins control various cellular mechanisms such as
cell cycle progression (King et al., 1996) and regulation of
transcription factors (Ciechanover, 2013). The ubiquitin
proteasome pathway not only degrades proteins but also
controls the carcinogenesis process at the molecular
level, including DNA repair mechanisms (Gallo et al.,
2017). The activity of ubiquitin ligases and deubiquitinase
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enzymes maintains the oncogenic pathways (Gallo et al.,
2017) which might control cancer initiation, progression,
or promotion. Several regulatory pathways, such as
the negative feedback mechanism of p53 protein, are
controlled by the ubiquitination process in breast cancer
(Mourtzoukou et al., 2018).
USP7 is a member of the ubiquitin specific protease
(USP) deubiquitination family; it interacts with many
other cellular proteins (Sowa et al., 2009). USP7
recycles associated proteins and prevents proteasomal
degradation via deubiquitination. USP7 interacts with
several proteins that are involved in the cell cycle, DNA
repair, and epigenetic mechanisms. Overexpression of
USP7 is observed in many types of cancers, indicating the
therapeutic potential of USP7 as a target (Wang, 2019).
Aberrant overexpression of USP7 has been observed in
breast cancer (Wang et al., 2016).
Identification of the ubiquitination pathways that
control breast cancer initiation, promotion, or progression
might be useful for clinics investigating new treatment
modalities. Development of gene editing techniques might
enable targeting strategies against ubiquitination pathways
to treat breast cancer. The current study aims to investigate
the promoting role of USP7 in breast cancer cell lines in
vitro using small-molecule–based inhibition and siRNA/
shRNA-based knockdown strategies to downregulate
USP7 in MCF7 and T47D cell lines in vitro.

USA) according to the described protocol. Briefly, cells
were seeded onto 12-well plates (5 × 104 cells/well) prior
to transfection and incubated until 80% confluence. Cells
were treated with 20 pmol of silencer siRNA negative
control (Thermo Fisher) and USP7 siRNAs for 48 h and
subjected to further experiments.
2.4. Cell viability assay
Effect of DUB inhibitor p5091 on cell viability of T47D and
MCF7 cells was measured with 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxy-methoxy-phenyl)-2-(4-sulfo-phenyl)2H-tetrazolium (MTS) assay (CellTiter96 AqueousOne
Solution; Promega UK Ltd., Southampton, UK). Briefly,
cells were seeded on 96-well plates (Corning Inc., Corning,
NY, USA) at a cell density of 5 × 103 cells/well. Cells were
treated with various concentrations of p5091 (2μM, 5μM,
10μM, and 20μM) for 24, 48, and 72 h. In order to measure
cell viability, cells were exposed to PBS containing 4.5 g/L
glucose and 10% MTS as described previously (Huang
et al., 2004). Absorbance rates at 490 nm, indicating
viability, were measured after 1–2 h incubation of cells in a
humidified incubator in darkness.

2.1. Cell lines
T47D (HTB-133), MCF7 (HTB-22), and HEK293T (CRL3216) cell lines were provided from the American Type
Culture Collection (ATCC, Rockville, MD, USA). T47D
cells were incubated in Roswell Park Memorial Institute
medium (RPMI, Gibco, Paisley, Scotland, UK); MCF7 and
HEK293T cells were incubated in Dulbecco’s Modified
Eagle’s Medium (DMEM, Gibco) supplemented with
10% fetal bovine serum (FBS, Gibco) and 1% penicillin/
streptomycin/amphotericin (PSA, Gibco). Cells were
incubated in a humidified incubator at 37 °C and 5% CO2.

2.5. Quantitative real-time PCR (qPCR) assay
Specific primers for ubiquitin-specific protease 7 (USP7),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
protein kinase B (Akt), Bcl–2-associated X protein
(BAX), B-cell lymphoma 2 (BCL2), caspase 3, caspase 7,
Forkhead box protein O4 (FOXO4), epidermal growth
factor receptor (EGFR), nuclear factor kappa B (NF-κB),
and mouse double minute 2 homolog (MDM2) (Table)
were designed with Primer-BLAST software (National
Center for Biotechnology, Bethesda, MD, USA) and
synthesized by Macrogen Inc. (Seoul, Korea). The SYBR
Green method was used to detect mRNA levels of the
target genes (Navarro et al., 2015). GAPDH was used as
a housekeeping gene. RNA was isolated using TRIZOL
(Invitrogen) according to the manufacturer’s instructions
and cDNA was synthesized using an iScript™ cDNA
Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA,
USA) and qPCR assay was performed by using a CFX96
RT-PCR system (Bio–Rad Laboratories Inc.).

2.3. siUSP7 transfection
USP7-specific small interfering RNA was purchased from
ThermoFisher Scientific (siRNA ID: 105065). Transfection
protocol was performed using Lipofectamine® RNAiMAX
(Thermo Fisher Scientific Inc., Invitrogen, Carlsbad, CA,

2.6. Western blot analysis
Change in USP7 protein expression and total ubiquitination
were determined by Western blot analysis. Total protein
was isolated by RIPA Lysis buffer; 30 µg proteins were
loaded on MiniPROTEAN Precast Gel (Bio-Rad
Laboratories Inc.) and transferred to PVDF membrane
(Bio-Rad Laboratories Inc.). Membranes were blocked
with TBST containing 5% Blotting Grade Blocker (BioRad Laboratories Inc.) for 1 h. USP7-specific antibody
(Cell Signaling Technology, Inc., Danvers, MA, USA) or
mono- and poly-ubiquitinated conjugates antibody (Enzo
Life Sciences GmbH, Lörrach, Germany) was applied

2. Materials and methods

2.2. Small molecule inhibitor preparation
DUB inhibitor (p5091, Selleckchem, Houston, TX, USA)
was prepared in dimethyl sulfoxide (DMSO, Sigma-Aldrich
Chemie GmbH, Hamburg, Germany) as described in the
literature (Tavana et al., 2018); 10 mM stock concentration
was prepared in DMSO, and further concentrations were
prepared in complete cell culture medium.
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Table. qPCR primer sequences.
Gene
USP7
MDM2
P53
BAX
BCL2
Caspase 3
Caspase 7
EGFR
PTEN
FOXO4
Akt
NF - κB
GAPDH

Side

Sequence

Forward

5’ GGAAGCGGGAGATACAGATGA 3’

Reverse

5’ AAGGACCGACTCACTCAGTCT 3’

Forward

5’ GGCTCTGTGTGTAATAAGGGAGA 3’

Reverse

5’ GGACTGCCAGGACTAGACTTTG 3’

Forward

5’ GCCCAACAACACCAGCTCCT 3’

Reverse

5’ CCTGGGCATCCTTGAGTTCC 3’

Forward

5’ TGCAGAGGATGATTGCCGCCG 3’

Reverse

5’ ACCCAACCACCCTGGTGTTGG 3’

Forward

5’ AACGGAGGCTGGGATGCCTTTGTG 3’

Reverse

5’ ACCAGGGCCAAACTGAGCAGAGT 3’

Forward

5’ GAGGCGGTTGTAGAAGAGTTCGTG 3’

Reverse

5’ TGGGGGAAGAGGCAGGTGCA 3’

Forward

5’ GGAGAAAGCTCATGGCTGTGT 3’

Reverse

5’ TCCCCTTGGCTGTGTTTTG 3’

Forward

5’ AATGCAACATCCTGGAGGGG 3’

Reverse

5’ AGGTGATGTTCATGGCCTGG 3’

Forward

5’ TGTGGTCTGCCAGCTAAAGG 3’

Reverse

5’ ACACACAGGTAACGGCTGAG 3’

Forward

5’ GACTGCGAGTCCATCATCCT 3’

Reverse

5’ GGGCTGAGTCGAAGTTGAAG 3’

Forward

5’ GAAGCTGCTGGGCAAGGGGCA 3’

Reverse

5’ GTGGGCCACCTCGTCCTTGG 3’

Forward

5’ GCCACCCGGCTTCAGAATGGC 3’

Reverse

5’ TATGGGCCATCTGCTGTTGGCAGT 3’

Forward

5’ AAGGTGAAGGTCGGAGTCAAC 3’

Reverse

5’ GGGGTCATTGATGGCAACAATA 3’

in blocking solution overnight (4 °C). Membrane was
incubated with antirabbit secondary antibody (dilution
1:5000, Santa Cruz Biotechnology Inc., Dallas, TX,
USA) for 2 h at room temperature and incubated with
Amersham ECL™ Detection Reagents (Sigma-Aldrich
Chemie GmbH) for 30 s. GAPDH was used as an internal
control and images were taken by using the luminometer
system (Bio-Rad Laboratories Inc.).
2.7. Colony forming unit (CFU) assay
Colony forming capability of the cells was determined via
CFU assay according to previously described protocol
(Digirolamo et al., 1999). T47D and MCF7 cell lines were
plated in 6-well plates (Corning Plasticware) at a cell
density of 300 cells/well in complete culture medium. After
24 h, cells were treated with 10 µM p5091 and siUSP7.
After 2 days for MCF7 and 3 days for T47D, media were
changed to growth medium and cells were incubated for

14 days until colony formation could be observed. Cells
were fixed with 4% paraformaldehyde and stained with
crystal violet. Images were taken with a ZEISS microscope
equipped with an AxioCam ICc 5 camera and using ZEN
2 (Blue edition) software.
2.8. Cell cycle analysis
In order to determine the effect of USP7 suppression on the
control of cell division, T47D and MCF7 cells were subjected
to cell cycle analysis according to the protocol (Demirci et
al., 2019). Briefly, cells were plated (3 × 105 cells/well) in
6-well tissue culture plates; after 24 h incubation, siRNA
or p5091 was applied to the cells. Cells were fixed with
4% paraformaldehyde and suspended in 500 μL staining
solution containing 40 μg/mL RNase A (Fisher Scientific
UK Ltd., Loughborough, UK), 33 μg/mL propidium iodide
(PI, Fisher Scientific UK Ltd., Loughborough, UK) and
0.2% nonyl phenoxypolyethoxylethanol [NP -40, Fisher
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Scientific UK Ltd., Loughborough, UK) in PBS]. Cells
were incubated in staining solution at 37 °C for 30 min,
and the cell cycle was analyzed using BD FACS Calibur
(BD Biosciences, Woburn, MA, USA).
2.9. Hanging drop assay
Sphere formation capability of breast cancer cells was
determined by hanging drop assay to detect whether USP7
suppression might block sphere formation in vitro (Kuo et
al., 2017). Cells were counted and diluted to 1 × 103 cells
per 40 μL of media containing 10 μL of 0.1% gelatin after
p5091 and siUSP7 administration. Cell and gelatin were
mixed well and transferred drop by drop to the lid of a
100-mm culture dish (Corning Plasticware). Each 40-μL
volume drop had an approximate diameter of 1.4 mm.
An appropriate amount of PBS was added into the culture
dish to minimize evaporation. The culture vessel lid with
the cell drops was gently flipped upside down to create
the gravitational force required for sphere formation.
After 24 h, spheres formed and were transferred into cellculture–compatible 24-well plates for examination under
the light microscope. Sphere diameter and thus sphere
dissemination were checked for in the following 2 days.
Images were taken with a ZEISS microscope equipped
with AxioCam ICc 5 camera and ZEN 2 (Blue edition)
software.
2.10. Scratch assay
To identify the changes in metastatic capacity, scratch
assay protocol was performed as described in the literature
(Doğan et al., 2014). Briefly, cells were seeded on 12-well
plate dishes (Corning Plasticware) as 105 cells/well in the
appropriate medium for each cell; they were allowed to
attach in a humidified 37 °C and 5% CO2-conditioned
incubator. The attachment of the cells was followed by
scratching a wound with a sterile 200-μL pipette tip.
Deattached cells were washed once with 1× PBS solution
followed by fresh medium addition, which included 10µM
p5091 or 20 pmol siUSP7. Images were taken via ZEISS
microscope, AxioCam ICc 5 camera, and the ZEN 2 (Blue
edition) computer application.
2.11. USP7 knockdown using shRNA
In order to investigate the effect of stable USP7 knockdown
on colony-forming capacity, USP7 protein was knocked
down with lentiviral shUSP7 vector (V3SH11252,
Dharmacon Inc., Cambridge, UK) according to the
procedure in the literature (Mali, 2013).
HEK293T cell line was transfected with the
combination of shUSP7 vector, lentiviral envelope plasmid
[pCI-VSVG (Addgene, MA, USA)], and packaging plasmid
(pCMV-dR8.2 dvpr [Addgene]) for lentiviral production
in the collected medium was examined with Lenti-x Go
Sticks (Takara Bio Inc., Shiga, Japan), according to the
manufacturer’s instructions. For transduction, MCF7 and
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T47D cells were cultured into 24-well plates (Corning
Plasticware) 24 h before viral infection at a density of 5 ×
104 cells per well. After overnight incubation, the culture
medium was refreshed with 1 mL of fresh complete media
containing viral particles (4 × 104 transducing units/mL)
and 10 μg/mL polybrene (Sigma-Aldrich Chemie GmbH).
Cells were incubated in a humidified incubator at 37 °C and
5% CO2 for 24 h. After observing GFP signals, transduced
cells were selected in complete growth medium containing
2 μg/mL puromycin (Sigma-Aldrich Chemie GmbH).
2.12. Statistical analysis
All experiments were conducted at least 3 times. Statistical
analyses were conducted using one-way ANOVA and
Tukey’s post hoc test using GraphPad Prism 7 software
(GraphPad Software Inc., San Diego, CA, USA). Statistical
significance was determined as * P < 0.05, ** P < 0.005, ***
P < 0.001.
3. Results
3.1. USP7 inhibition decreases cell viability
MTS assay was performed to understand the effect of
USP7 inhibitor p5091 on the cell viability of breast cancer
cell lines for 3 days. Different concentrations (2µM, 5µM,
10µM, and 20µM) of p5091 were tested on T47D and
MCF7 cell lines. Results have shown that cell viability
was reduced in a concentration-dependent manner, and
10µM p5091 caused an approximately 50% decrease in
T47D (Figure 1a) and MCF7 (Figure 1b) cell viability
after 3 and 2 days of treatment, respectively (Figure 1c).
Small-molecule–inhibitor p5091 treatment had no effect
on USP7 protein level in either MCF7 (after 48 h of
treatment) or T47D (after 72 h of treatment) as expected,
since p5091 reduces enzyme activity instead of decreasing
the protein amount. However, total ubiquitination levels
significantly increased (≈4 fold) (Figure 1d), indicating
the inhibition of USP7 activity in vitro for the selected
concentration of p5091 (10µM). CFU assay was performed
to identify the alterations in colony-forming ability of
the breast cancer cells after allosteric inhibition of USP7
(Figure 1e). The results demonstrated that blocking the
activation of USP7 in MCF7 cells reduced the diameter of
colonies approximately 45% compared to control (Figure
1f). Moreover, USP7 inactivation decreased the diameter
of the colonies approximately 85% in cultured T47D cells
(Figure 1g). The number of MCF-7 and T47D colonies
dramatically decreased in p5091-treated cells. Although
growth-medium–treated negative control cells formed 420
colonies, the p5091 group formed 11 colonies in MCF-7
cells (Figure 1h). Similar results were obtained in T47D
cells as well; the number of colonies decreased from 212
to 9 (Figure 1i).
Apart from the inhibition of USP7 activity via smallmolecule inhibition, siRNA knockdown strategy was used
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Figure 1. p5091 blocks cell proliferation and CFU formation in vitro. (a) Cell viability analysis of p5091 treated T47D cells. (b) Cell viability analysis of
p5091 treated MCF7 cells. (c) Cell viability analysis of 10µM p5091 treated MCF7 and T47D cells. (d) Western blot analysis of MCF7 and T47D cells
after 10µM p5091 administration. 30µg of total protein was blotted with anti-USP7 and antiubiquitin antibodies. Anti-GAPDH antibody was used for
loading control. (e) Experimental design of CFU analysis after p5091 treatment. (f) Microscopic images of CFU assay after 10µM p5091 treatment for 48
h in MCF7 and (g) for 72 h in T47D. (h) Number of the colonies and diameter of the colonies after 48 h of p5091(10µM) treatment in MCF7 and (i) 72
h of p5091 (10µM) treatment in T47D cells. * P < 0.05, *** P < 0.001, scale bar: 400µm (5x), 200µm (10x). NC: Negative control, number of replicates: 3.
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to reduce USP7 at the molecular level to understand the
regulatory role of USP7 on breast cancer cell proliferation
and growth in vitro. Viable cell counts were calculated after
siRNA treatment to observe cell proliferation followed by
USP7 knockdown. siUSP7 treatment decreased the cell
viability of MCF7 cells from 180 × 103 living cells to 40
× 103 cells (77.78% reduction) (Figure 2a). Similarly, the
viable T47D cell number decreased from 245 × 103 to
165 × 103, a 32.65% decrease (Figure 2b). The efficacy of
siUSP7 strategy was examined by Western blot analysis.
USP7 protein levels decreased 5-fold and 3-fold for
MCF7 (Figure 2c) and T47D (Figure 2d), respectively.
Additionally, CFU assay was performed to examine the
alterations in stemness capability after silencing USP7
protein level by specific siRNA (Figure 2e). However, there
was no significant change in the morphology of MCF7
(Figure 2f) and T47D (Figure 2g) colonies. Similarly, no
significant change was observed in CFU ability of MCF7
and T47D after siRNA treatment, indicating that the effect
of siRNA-based gene downregulation of USP7 in MCF7
(Figure 2h) and T47D (Figure 2i) cells was transient.
Furthermore, stable knockdown of USP7 was performed
to prove that a loss of USP7 function decreases colonyforming capacity, but the regaining of USP7 enzyme
activity can restore the stemness of cells (Supplementary
1). The successful transfection of shUSP7 and control
vector (Scrambled) was shown via fluorescent microscopy
images in MCF7 cell lines (Supplementary Figure 1a).
USP7 protein level decreased by nearly 60% compared to
GAPDH (Supplementary Figure 1b). Moreover, CFU assay
in the MCF7 cell line (Supplementary Figure 1c) showed
that stable knockdown of USP7 decreased colony numbers
from 15 to 3 (Supplementary Figure 1d); an approximately
6-fold decrease was observed in the diameter of the
colonies (Supplementary Figure 1e). Additionally, the
shUSP7-transfected T47D cell line (Supplementary Figure
1f) expressed a significantly decreased amount of USP7
(~5 fold) (Supplementary Figure 1g). The obtained CFU
assay results in the T47D cell line (Supplementary Figure
1h) demonstrated that stable USP7 knockdown decreased
colony numbers by 90% (Supplementary Figure 1i) and
diameters by 50% (Supplementary Figure 1j).
3.2. USP7 controls cell cycle
USP7 inactivation caused alterations in cell cycle
regulation of breast cancer cell lines. The obtained DNA
histograms showed that MCF7 cells accumulate in G1
phase after p5091 treatment and the cell number difference
between the control group and the p5091-treated group
was calculated as 11.54%. In addition to this, after 10µM
of p5091 treatment, 11.86% reduction was observed in
the number of MCF7 cells that are in G2/M phase (Figure
3). Although no significant change was observed at S
phase of the T47D cells, 14.45% difference was observed
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in accumulated cells in G1 phase after p5091 treatment.
Cell cycle analysis also revealed that 17.62% of control
T47D cells were in G2-M phase. In contrast, only 7.89% of
p5091-treated T47D cells were in G2/M phase (Figure 3).
USP7 knockdown by siRNA altered the cell cycle
profile of MCF7 and T47D cell lines as well. The number
of MCF7 cells in G1 phase was increased by 5.48%, and
a 7.24% decrease was found in the number of the cells in
G2/M phase after the USP7 level was reduced. However,
no significant change was observed at S phase after siRNA
application. Therefore, the decreased USP7 amount caused
an arrest in G1 phase and a decrease in G2/M phase in
MCF7 cells (Figure 3). A similar effect was also observed
in T47D. G1 and S phases of T47D cells were expanded
by 5.56% and 3.06% after siUSP7 application, respectively.
Moreover, the number of the T47D cells in G2/M phase
decreased by 8.88% after siUSP7 administration (Figure
3). Consequently, cell cycle results were found to be in
agreement with the proliferation assay results.
3.3. Cell migration capacity of breast cancer cells might
be regulated by USP7
The effect of USP7 downregulation on migratory phenotype
was evaluated by sphere formation and dissemination
analysis. The results demonstrated that dissemination
of the p5091- and siRNA-treated spheres was decreased
dramatically in both MCF7 and T47D cells (Figure 4a).
Inhibition of USP7 activity by p5091 and siRNA
treatment diminished the migration capacity of both
MCF7 and T47D cells, resulting in reduced sphere
diameter after 24 h and 48 h compared to control. p5091treated spheres were 37.5% smaller after 24 h in MCF7
cells and 45% smaller in T47D cells compared to baseline
(Figure 4b).
The difference between control and p5091 groups
was more obvious after 48 h; 40% and 60% reduction
in spheres size were observed in MCF7 and T47D cell
cultures, respectively (Figure 4b).
Although siRNA treatment did not cause a significant
change in cell migration of MCF7 cells after 24 h, a 30%
decrease in the diameter of siUSP7-treated spheres
was observed after 48 h, indicating maximum gene
downregulation at day 2 following siRNA treatment
(Figure 4b). However, siUSP7 exerted 35% and 46%
reduction at 24 h and 48 h respectively in T47D spheres
(Figure 4b).
Sphere dissemination of MCF7 and T47D cultures
was determined via intensity measurements (Figure 4c).
Less intensity is an indicator of cell migration on the
tissue culture plate surface. Intensity analysis of cell lines
was followed by the calculation of difference in sphere
intensity, which was found to be negatively correlated with
tumor dissemination for both T47D and MCF7 cell lines.
USP7 protein inhibition by p5091 resulted in more intense
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Figure 2. siRNA application blocks cell proliferation in vitro. (a) Viable cell count analysis after 48 h of 20 pmol siRNA treatment in MCF7 and T47D
cells. (b) Cell viability analysis of 20 pmol siRNA administration in MCF7 and T47D cells for 2 days. (c) Western blot analysis of MCF7 cells after 2 days
of 20 pmol siRNA application. 30µg of total protein was blotted with anti-USP7 antibody. Anti-GAPDH was used for loading control. (d) Western blot
analysis of T47D cells after 2 days of 20 pmol siRNA application. 30µg of total protein was blotted with anti-USP7 antibody. Anti-GAPDH was used
for loading control. (e) Experimental design of CFU analysis after siUSP7 application. Cells were treated with 20 pmol siRNA for 2 days and culture
media was refreshed after every 48 h for 14 days. (f) Microscopic images of CFU assay after transient USP7 knockdown in MCF7 and (g) T47D cells.
(h) Number of the colonies and diameter of the colonies after transient USP7 knockdown in MCF7 and (i) T47D cells. * P < 0.05, scale bar: 400µm (5x),
200µm (10x). siControl: Control small interfering RNA, siUSP7: USP7 small interfering RNA, number of replicates: 3.
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Figure 3. Allosteric inhibition and transient knockdown of USP7 alters cell cycle profile of MCF7 and T47D cells. MCF7 cells were
treated with 10µM of p5091 for 2 days and T47D cells were treated with 10µM of p5091 for 72 h. Both of the cell lines were treated with
20 pmol siRNA for 48 h. NC: Negative control, siControl: Control small interfering RNA, siUSP7: USP7 small interfering RNA, number
of replicates: 3.

spheres in both MCF7 and T47D cell lines even after 48
h of incubation. Similarly, knockdown of USP7 induced
sphere intensity for both of the cell lines (Figure 4c).
Correlatively, tumor sphere dissemination calculations
of MCF7 demonstrated that USP7 inactivation decreased
tumor dissemination by 42% after p5091 treatment and
32% after USP7 knockdown (Figure 4d). Similarly, siUSP7
application decreased dissemination by 44%, and p5091
treatment decreased tumor dissemination by 32% in T47D
cells (Figure 4d). These results supported the negative
correlation between tumor dissemination and intensity
measurements (Figure 4e). In addition, scratch assay (in
vitro cell migration) was performed to determine the
effect of USP7 on cell migration (Supplementary Figure 2).
The obtained results clearly highlight that deactivation of
USP7 protein with its allosteric inhibitor p5091 decreased
gap closure capability of MCF7 cells by 87.5%. Similarly,
p5091 treatment decreased the gap closure capability of
T47D cells by 95%. Additionally, compared to the control
siRNA group, siUSP7 application also decreased the
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wound healing capacity of MCF7 and T47D cell lines by
64% and 66%, respectively (Supplementary Figure 2).
3.4. USP7 changes gene expression profile
qPCR experiments have clearly shown that p5091
treatment did not cause any significant change in USP7,
MDM2, BAX, BCL2, PTEN, EGFR, and AKT gene
expression levels in the MCF7 cell line. However, 3-fold
upregulation of TP53 gene expression was observed as
an apoptotic marker. CASP3 and CASP7 gene expression
levels were increased by 1.9-fold and 1.8-fold respectively
as late apoptosis indicators. An approximately 2-fold
increase was observed for both FOXO4 and NF-kB mRNA
levels (Figure 5a).
siUSP7 treatment on MCF7 cells led to a dramatic
decrease in USP7 gene expression (5-fold decrease) as
expected. USP7 decrease had no noticeable effect on
PTEN, FOXO4, TP53, MDM2, BAX, BCL2, PTEN, EGFR,
FOXO4, AKT, and NF-kB genes which might be explained
by the transient downregulation of the USP7 gene. On
the other hand, CASP 3 and CASP 7 mRNA levels were
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Figure 4. USP7 enzyme plays a critical role in tumor dissemination. (a) Microscopic images of tumor sphere dissemination profile
after allosteric inhibition and transient knocking-down of USP7 in MCF7 and T47D cells. (b) Sphere diameter measurements of MCF7
and T47D cell lines after 10µM p5091 treatment (48 h for MCF7 and 72 h for T47D) and 2 days of siRNA (20 pmol) application. (c)
Histogram representation of intensity measurements of MCF7 and T47D cells after 10µM p5091 administration (MCF7 for 48 h and
T47D for 72 h) and 20 pmol of siRNA application for 2 days. (d) Tumor dissemination percentages of MCF7 and T47D cell lines
after allosteric inhibition and transient knocking-down of USP7 enzyme. (e) Illustrated chart of the correlation between tumor sphere
dissemination intensity and USP7. * P < 0.05, ** P < 0.005, *** P < 0.001, scale bar: 400µm (5x). NC: Negative control, siControl: Control
s mall interfering RNA, siUSP7: USP7 small interfering RNA, number of replicates: 5.

found to be increased 6.8-fold and 4.4-fold, respectively,
indicating that the cells were going through apoptosis
(Figure 5b).
p5091 treatment had a similar effect on the gene
expression profile of T47D cells. USP7, BCL2, CASP7,
and PTEN gene expressions did not change. Additionally,
increased FOXO4 (3.9-fold), CASP 3 (≈2.5-fold), CASP
7 (≈2-fold), TP53 (2-fold), and MDM2 (1.8-fold) mRNA
levels were observed as an indicator of apoptosis. p5091
caused a 5.7-fold increase in BAX, which is a proapoptotic
gene (Figure 5c). siUSP7 treatment not only caused a
decrease in UPS7 (10-fold), but also in reduced MDM2
(10-fold), BCL2 (5-fold), Akt (14.3-fold), and NF-kB (2.13fold) gene expression in T47D cells. Similarly, increases in
TP53 (3.4-fold), CASP3 (6.5-fold), and CASP 7 (4.2-fold)
mRNA levels were observed as an indicator of apoptosis
(Figure 5d).

4. Discussion
The ubiquitination pathway, as an important molecular
mechanism for protein function, is involved in nearly every
molecular process, such as the TP53-MDM2 pathway
(Oren, 2003), which is crucial for apoptosis. Recent studies
have focused on the inhibition of E3 ligases to rescue
proteins from ubiquitination (Brahemi et al., 2010) and
deubiquitination enzymes (DUBs) which are responsible
for controlling the 26S proteasomal degradation (Amerik
and Hochstrasser, 2004). Regulation of the ubiquitination
process is mainly conducted by DUBs since not only do
they deattach the ubiquitin tags from the protein, they also
block the ubiquitination sides on proteins (Hoeller and
Dikic, 2009). USP7, which is a member of the ubiquitinspecific protease deubiquitination family, is a unique
example for the relevant regulation (Nijman et al., 2005).
Thus, in the current study, we have aimed to identify USP7,
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a.

b.

Figure 5. Comparison of mRNA expression levels of USP7, MDM2, TP53, BAX, BCL2, CASP3, CASP7, PTEN, EGFR, FOXO4, Akt and
NF-κB in experimental groups. (a) Changes in gene expression profiles of MCF7 cell line after 2 days of p5091 (10µM) treatment and
(b) 2 days of siRNA (20 pmol) administiration. (c) Alterations in gene expression profiles of T47D cell line after 3 days of p5091 (10µM)
treatment and (d) 2 days of siRNA (20 pmol) administiration. * P < 0.05, ** P < 0.005, *** P < 0.001. NC: Negative control, siControl:
Control s mall interfering RNA, siUSP7: USP7 small interfering RNA, USP7: Ubiquitin specific processing protease 7, MDM2: Mouse
double minute 2 homolog, BAX: Bcl–2-associated X protein, BCL2: B-cell lymphoma 2, CASP3: Caspase 3, CASP7: Caspase7, PTEN:
Phosphatase and tensin homolog, EGFR: Epidermal growth factor receptor, FOXO4: Forkhead box protein O4, Akt: Protein kinase B,
NF-κB: Nuclear factor kappa B, number of replicates: 3.

which is a deubiquitination enzyme, as a new therapeutic
target for breast cancer treatment regardless of TP3
mutation in vitro. Previous studies have demonstrated
that p5091, which is a specific inhibitor of USP7, blocks
cell proliferation of different types of cancers such as
ovarian (Wang et al., 2017), prostate (Morra et al., 2017),
and breast cancers (Xia at al., 2019). Our results show
that suppression of USP7 activity via p5091 and siUSP7
caused a decrease in cell proliferation for both MCF7 and
T47D cell lines regardless of their TP53 mutation status.
CFU results also supported the cell proliferation data.
Furthermore, the effect of p5091 on CFU was replicated

154

with a colony-forming unit assay in which USP7 was
knocked down stably, as there was no significant change in
CFU capacity after transient knockdown of USP7.
Our results have shown that allosteric inhibition of
USP7 did not change the USP7 level as expected (Carra
et al., 2017), but enhanced the amount of the total
ubiquitination in the cell, which confirms the deactivation
of the USP7 enzyme. A decrease in USP7 enzyme activity
altered the expression profiles of apoptotic genes as
expected (Hu et al., 2019). Gene expression levels of TP53
and CASP3 in both MCF7 and T47D cell lines increased
dramatically. It is known that the negative feedback
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mechanism of p53 protein is regulated by USP7 enzyme
activity due to its interaction with Mdm2 protein
(Wang 2019). Moreover, decreasing USP7 enzyme
activity increases the self-ubiquitination capacity of the
Mdm2 enzyme (Song et al., 2008). Thus, USP7 decrease
resulted in noticeable upregulation of TP53 gene
expression. A recent study has shown that inhibition
of USP7 increases the Bax protein level in the MCF7
cell line, which harbors wild-type p53 protein (Xia at
al., 2019). It is known that the activation of Bax protein
can be controlled by p53 protein (Chen, 2016); the
activated Bax protein increases apoptosis through the
mitochondrial pathway (Borner and Andrews, 2014).
Our results demonstrated that expression level of the
BAX gene dramatically increased in the p53-mutated
T47D cell line after inactivation of USP7; this increase
may also support that the effect of USP7 inactivation is
independent of p53.
Transient silencing of USP7 was found to be more
efficient in overexpression of caspases 3 and 7, which
are known as executioner caspases and are highly
correlated with apoptosis (Liu et al., 2016). Surprisingly,
USP7 knockdown decreases MDM2, AKT, and NFκB gene expression levels in the T47D cell line, which
harbors the p53 mutation. It is known that Mmd2 can
be activated by Akt protein (Nakanishi et al., 2014)
and that the activated Mdm2 is responsible for p53
degradation (Gupta et al., 2019). Additionally, it was
found that p53 protein is suppressing NF-κB protein
in lung cancer cell lines (Dey et al., 2007). However,
our results show that USP7 knockdown decreases the
expression levels of MDM2, AKT, and NF-κB genes
without being dependent on p53 protein.
Kessler et al. (2007) showed that knockdown of
USP7 is responsible for some major alterations in
the function of different proteins that participate in
cellular events, including cell cycle regulation and DNA
replication in colorectal adenocarcinoma. Furthermore,
increased p21 level was observed after inactivation of
USP7 by p5091 in ovarian cancer (Wang et al., 2017). In
the current study, remarkable cell accumulation at the
G0–G1 phases was observed after USP7 inactivation
in MCF7 and T47D cell lines. This accumulation is in
positive correlation with the literature showing that
USP7 inhibition causes a G0–G1 arrest in breast cancer
cell lines (Xia at al., 2019).
Three-dimensional tumor sphere formation, cell
surface attachment, and migration of cells from the
sphere to the surrounding extracellular matrix are
used to mimic carcinogenic phenotype, metastasis, and
invasion (Weiswald et al., 2015; Hosseini et al., 2016).
Moreover, alterations in sphere intensity were measured

daily as migrated spheres become less intense. Inhibition
of USP7 via p5091 administration or downregulation by
siUSP7 siRNA disrupted sphere integrity; it inhibited
cell migration from spheres and as a result increased
the sphere intensity.
To assess whether proliferative features of cancer
cells and metastatic potential could be actually
decreased by a differential amount of USP7, scratch
assay was performed. It is indicated in the literature
that MCF7 and T47D cells migrate less to the wounded
area after silencing the several factors that have positive
effects on cell proliferation (Yoshimura et al., 2016).
Both MCF7 and T47D cell lines migrated to the
scratched area significantly less after inhibition of USP7
enzyme activity by p5091 or siUSP7. Therefore, it has
been proven that USP7 enzyme activity is necessary for
cellular metastasis. Although an indirect correlation
between USP7 and the metastasis of gastric cancer has
been shown previously by altering the levels of USP7
mediated histone demethylase PHF8 (Li et al., 2017),
our study demonstrated the direct correlation between
USP7 enzyme activity and cancer cell migration ability
in a p53-independent manner for the first time.
5. Conclusion
Overall, USP7 as a deubiquitination enzyme might be a
molecular regulator in breast cancer and could be a target
for future gene-editing strategies. Downregulation of
USP7 activity, which resulted in a significant increase of
apoptosis-related genes, blockage of cell proliferation,
and reduced cell migration, showed remarkable
anticancer activity in both MCF7 and T47D cell lines.
The potential anticancer activity of USP7 was shown
to be p53-independent in vitro; it should be studied in
detail by RNA seq transcriptomic analysis in various
breast cancer and healthy breast epithelium cell types.
Identification of USP7 as a therapeutic target might
be possible through detailed gene editing analysis on
more invasive breast cancer cell lines and healthy breast
epithelial cell lines. In vivo tumor formation and gene
therapy strategies are necessary to understand the exact
molecular mechanism underlying the regulatory role of
USP7 on tumor formation and progression.
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Supplementary Figure 1. Stable knockdown of USP7 blocks CFU formation in vitro. (a) Fluorescent and bright filtered images of MCF7 after lentiviral
infection. Both scrambled and shUSP7 plasmids have green fluorescent protein genes. (b) Total USP7 protein levels of MCF7 cell line after targeting
USP7 protein by lentiviral shRNA vector. GAPDH antibody was used as a loading control. (c) Microscopic images of CFU assay after knocking down
USP7 in MCF7 cells. (d) Number of the colonies and (e) diameter of the colonies after USP7 knock down in MCF7 cells. (f) Fluorescent and bright
filtered images of T47D after lentiviral infection with scrambled and shUSP7 plasmids which both have green fluorescent protein genes. (g) Total USP7
protein levels of T47D cell line after targeting USP7 protein by lentiviral shRNA vector. GAPDH antibody was used as a loading control. (h) Microscopic
images of CFU assay after knocking down USP7 in T47D cells. (i) Number of the colonies and (j) diameter of the colonies after knocking down USP7
in T47D cells. *P < 0.05, ***P < 0.001, scale bar: 400µm (5x), 200µm (10x). NC: Negative Control, shUSP7: USP7 specific short hairpin RNA, number
of replicates: 3.
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Supplementary Figure 2. Allosteric inhibition and transient knockdown of USP7 decreases gap closure percentages thus migration
capacity of MCF7 and T47D cells. 10µM of p5091 and 2 days siRNA treatment were applied. ***P < 0.001, scale bar: 200µm. NC:
Negative control, siControl: Control small interfering RNA, siUSP7: USP7 small interfering RNA, number of replicates: 3.
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